{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:14:45Z","timestamp":1791616485467,"version":"4.3.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gilead Sciences, under Dr. John Martin\u2019s leadership, created its Global Access Program to deliver high-quality, affordable medicines to treat and ultimately eliminate some of the world\u2019s most challenging-to-treat, pervasive, life-limiting diseases not as philanthropy but based on a self-sustaining business model\u2014a highly novel concept in the pharmaceutical realm. John was determined to bring together all key stakeholders from public health officials to doctors and patients around the globe to understand barriers and opportunities in HIV, viral hepatitis, and visceral leishmaniasis (VL) and in so doing, pushed the Gilead team to devise novel strategies to address healthcare disparities in resource-challenged geographies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This case study provides an overview of the evolution and impact of the Gilead Access to Medicines Program in providing treatments for HIV in low- and lower middle-income countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535211068617","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T03:06:08Z","timestamp":1651460768000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7734-3883","authenticated-orcid":false,"given":"Gregg","family":"Alton","sequence":"first","affiliation":[{"name":"Formerly Chief Patient Officer at Gilead Sciences, Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Samuel","sequence":"additional","affiliation":[{"name":"Formerly, Senior Vice President, Global Patient Solutions at Gilead Sciences, Inc.,San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Reddi","sequence":"additional","affiliation":[{"name":"VP, Head of Corporate Strategy and External Affairs & Engagement, Adverum Biotechnologies, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"bibr1-13596535211068617","unstructured":"CDC. Pneumocystis Pneumonia - Los Angeles [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. 1981: [cited 2021 Sep 16]. Available from https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/june_5.htm"},{"key":"bibr2-13596535211068617","unstructured":"National Institute on Drug Abuse. What is haart? [Internet]. 2020; [cited 2021 Sep 16]. Available from https:\/\/www.drugabuse.gov\/publications\/research-reports\/hivaids\/what-haart"},{"key":"bibr4-13596535211068617","unstructured":"FDA Approves Gilead\u2019s Anti-HIV Drug Viread.\n                      Biotech Business\n                      [Internet]. 2001; 14(12):1 [cited 2021 Sep 15]."},{"key":"bibr5-13596535211068617","unstructured":"Hitchens K. HIV treatment advances with the first drug in a new class NEW DRUG.\n                      Drug Topics\n                      [Internet] 2001; 145(22):17 [cited 2021 Sep 15]."},{"key":"bibr7-13596535211068617","unstructured":"Bloom DE, Rangan VK, Rangan V. Gilead: Hepatitis-C Access Strategy (A). Harvard Business School Cases [Internet] 2014: 1. [cited 2021 Sep 16]."},{"key":"bibr8-13596535211068617","unstructured":"Lee K, Rangan VK. Gilead Sciences, Inc.: Access Program [Internet]. Harvard Business School Cases 2009: 1. [cited 2021 Sep 15]."},{"key":"bibr9-13596535211068617","unstructured":"UNAIDS. [Internet]. 2008 Report on the Global AIDS Epidemic. UNAIDS Joint United Nations Programme on HIV\/AIDS, 2008; [cited 2021 Sep 15]. Available from https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/jc1510_2008globalreport_en_0.pdf"},{"key":"bibr10-13596535211068617","unstructured":"President's Emergency Plan for AIDS Relief (PEPFAR) [Internet].\n                      Avert\n                      2006 [cited 2021 Sep 15]. Available from https:\/\/www.avert.org\/professionals\/hiv-around-world\/global-response\/funding"},{"key":"bibr11-13596535211068617","unstructured":"The Global Fund to Fight AIDS, Tuberculosis and malaria [Internet]. Home - the Global Fund to Fight AIDS, Tuberculosis and Malaria. 2021: [cited 2021 Sep15]. Available from https:\/\/www.theglobalfund.org\/en\/"},{"key":"bibr12-13596535211068617","unstructured":"The Medicines Patent Pool and GILEAD Sciences Sign licence For Bictegravir [Internet]. The Medicines Patent Pool. UNITAID; 2020: [cited 2021 Sep16]. Available from https:\/\/medicinespatentpool.org\/news-publications-post\/the-medicines-patent-pool-and-gilead-sciences-sign-licence-for-bictegravir\/"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211068617","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535211068617","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211068617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:05Z","timestamp":1777380785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535211068617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/13596535211068617"],"URL":"https:\/\/doi.org\/10.1177\/13596535211068617","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"article-number":"13596535211068617"}}